Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB

PLoS ONE

Volumn 5, Issue 12, 2010, Pages 1-9

  Dai, Yao ^a,d   Desano, Jeffrey ^a   Tang, Wenhua ^a,b   Meng, Xiaojie ^a,b   Meng, Yang ^a   Burstein, Ezra ^c   Lawrence, Theodore S ^a   Xu, Liang ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE; CELASTROL; ENZYME INHIBITOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHARMACOLOGY; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA; PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR RELA; TRIPTERINE; TRITERPENE;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG THERAPY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; METABOLISM; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; TUMOR CELL LINE;

ANDROGENS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG THERAPY; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; METABOLISM; MICE; MICE, NUDE; NF-KAPPA B; PHARMACOLOGY; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRITERPENES;

MUS MUSCULUS;

EID: 78650733125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014153     Document Type: Article

References (46)

1. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, et al. (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
2. Li B, Dou QP (2000) Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 97: 3850-3855.
3. Opferman JT (2006) Unraveling MCL-1 degradation. Cell Death Differ 13: 1260-1262.
4. Karnak D, Xu L (2010) Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets 11: 699-707.
5. Chen LF, Greene WC (2004) Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 5: 392-401.
6. Habraken Y, Piette J (2006) NF-kappaB activation by double-strand breaks. Biochem Pharmacol 72: 1132-1141.
7. Suh J, Rabson AB (2004) NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 91: 100-117.
8. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, et al. (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115: 141-151.
9. Dai Y, Lawrence TS, Xu L (2009) Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 1: 4-18.
10. Papandreou CN, Logothetis CJ (2004) Bortezomib as a potential treatment for prostate cancer. Cancer Res 64: 5036-5043.
11. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, et al. (2003) Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2: 835-843.
12. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese ''Thunder of God Vine,'' is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
13. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, et al. (2003) Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 67: 1883-1887.
14. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, et al. (2006) Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinine methide triterpenoid. Biochem Pharmacol 72: 1311-1321.
15. Sethi G, Ahn KS, Pandey MK, Aggarwal BB (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109: 2727-2735.
16. Chen M, Rose AE, Doudican N, Osman I, Orlow SJ (2009) Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res 7: 1946-1953.
17. He D, Xu Q, Yan M, Zhang P, Zhou X, et al. (2009) The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 9: 343.
18. Zhou YX, Huang YL (2009) Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J (Engl) 122: 1666-1673.
19. Pang X, Yi Z, Zhang J, Lu B, Sung B, et al. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/Mammalian Target of Rapamycin pathway. Cancer Res 70: 1951-1959.
20. Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, et al. (2004) Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate 60: 98-108.
21. Wu X, Li M, Qu Y, Tang W, Zheng Y, et al. (2010) Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg Med Chem 18: 3812-3822.
22. Meng Y, Tang W, Dai Y, Wu X, Liu M, et al. (2008) Natural BH3 mimetic (-)- gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 7: 2192-2202.
23. Lian J, Karnak D, Xu L (2010) The Bcl-2-Beclin 1 interaction in(-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy 6, 2010 (in press).
24. Lian JWX, He F, Karnak D, Tang W, Meng Y, Xiang D, Ji M, Lawrence TS, Xu L (2010) A natural BH3-mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 2010 (in press).
25. Dai Y, Liu M, Tang W, Li Y, Lian J, et al. (2009) A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 9: 392.
26. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, et al. (2009) Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys 74: 1217-1225.
27. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816.
28. Dai Y, Liu M, Tang W, Desano J, Burstein E, et al. (2008) Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 14: 7701-7710.
29. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, et al. (2005) Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24: 344-354.
30. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, et al. (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65: 6294-6304.
31. Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, et al. (2006) Down- regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107: 2354-2363.
32. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360.
33. Dai Y, Lawrence TS, Xu L (2009) Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 1: 1-15.
34. Pajonk F, Pajonk K, McBride WH (1999) Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 91: 1956-1960.
35. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, et al. (2004) Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18: 1357-1363.
36. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, et al. (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597.
37. Yang-Yen HF (2006) Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci 13: 201-204.
38. Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, et al. (2008) A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 27: 721-731.
39. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, et al. (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67: 5418-5424.
40. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, et al. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257-264.
41. Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, et al. (2005) Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 105: 3255-3262.
42. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ (2006) Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXA. Cancer Res 66: 9636-9645.
43. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, et al. (2008) Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 8: 1053-1072.
44. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 104: 19488-19493.
45. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293.
46. An WG, Hwang SG, Trepel JB, Blagosklonny MV (2000) Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14: 1276-1283.